Rutul Shah Sells 32,739 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 32,739 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $6.86, for a total transaction of $224,589.54. Following the completion of the transaction, the chief operating officer owned 465,012 shares in the company, valued at $3,189,982.32. The trade was a 6.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Precigen Trading Up 4.6%

Shares of PGEN stock opened at $7.23 on Friday. The company has a quick ratio of 4.12, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. Precigen, Inc. has a fifty-two week low of $1.70 and a fifty-two week high of $7.26. The firm’s 50 day moving average price is $5.23 and its two-hundred day moving average price is $4.50. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -6.95 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The company had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.98 million. The business’s revenue was up 6322.7% compared to the same quarter last year. On average, analysts anticipate that Precigen, Inc. will post 0.05 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PGEN shares. HC Wainwright boosted their price objective on Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen upgraded Precigen from a “hold” rating to a “strong-buy” rating in a report on Saturday. Citizens Jmp boosted their price target on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Finally, Zacks Research raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.50.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

Hedge Funds Weigh In On Precigen

Institutional investors and hedge funds have recently bought and sold shares of the stock. State of Wyoming acquired a new stake in shares of Precigen in the 1st quarter worth approximately $27,000. NBC Securities Inc. acquired a new position in shares of Precigen during the fourth quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Precigen during the third quarter valued at approximately $39,000. Royal Bank of Canada raised its holdings in Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,426 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Precigen in the third quarter worth approximately $41,000. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.